Predetermined change control plans for machine learning-enabled medical devices

AI Summary

In a collaborative effort, the U.S. Food and Drug Administration (FDA), Health Canada, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) have released five guiding principles for Predetermined Change Control Plans (PCCPs). This guidance addresses the regulatory framework necessary for managing the rapid, iterative modifications common in software as a medical device (SaMD) and artificial intelligence (AI) technologies. Unlike traditional rigid approval processes, PCCPs allow manufacturers to define future updates and the methodologies used to implement them at the time of initial review. The principles emphasize that plans must be focused, specific, and bounded, ensuring that changes do not negatively impact safety or performance. While this document is a policy guidance rather than an inspection report for a specific company, it establishes the expectations for manufacturers worldwide. Required actions for industry participants involve adopting these harmonized standards to facilitate predictable regulatory pathways. By following these principles, developers can ensure that their machine learning models and software tools remain clinically validated as they evolve. This joint approach by the FDA, MHRA, and Health Canada aims to foster innovation while maintaining rigorous oversight, providing a clear roadmap for the lifecycle management of next-generation medical technologies.